Ten Years On, Access To Biosimilars Still Patchy in EU
Executive Summary
April saw the 10th anniversary of the first biosimilar approval in Europe –Sandoz International GMBH's Omnitrope (somatropin) – which was launched in 2006. But a decade on, even with 20 biosimilar products now available and many more to come as big biological drugs lose their patent protection, there are still significant barriers to biosimilar penetration and wide variations in patient access across the EU that need to be addressed.
You may also be interested in...
Biogen Adds To Biosimilar Anti-TNF Portfolio In Europe With Flixabi
Samsung Bioepis’s biosimilar infliximab, Flixabi, has been approved for marketing in Europe, where it will add to Biogen's marketed biosimilar TNF-inhibitor etanercept to give the company two cost-effective TNF-inhibitors to offer to patients and hard-pressed healthcare systems.
Biogen Adds To Biosimilar Anti-TNF Portfolio In Europe With Flixabi
Samsung Bioepis’s biosimilar infliximab, Flixabi, has been approved for marketing in Europe, where it will add to Biogen's marketed biosimilar TNF-inhibitor etanercept to give the company two cost-effective TNF-inhibitors to offer to patients and hard-pressed healthcare systems.
Tiny Mabion Races Big Pharma To EU Rituximab Market
Poland’s biotech Mabion is racing to the European biosimilar market with a biosimilar rituximab, but is up against multinational biosimilar companies like Sandoz and South Korea’s Celltrion, and will likely need a strong commercialization partner outside its home market.